59 Drug Discovery & Pharmaceuticals Essential Tools for COVID-19 Omicron Research


AMSBIO has introduced further essential tools for SARS-CoV-2 researchers to help decipher the COVID-19 B.1.1.529 variant. New to the AMSBIO range are recombinant proteins, easy-to-perform assay kits, Omicron pseudotyped lentiviruses and spike neutralising antibodies for use in functional assays to block SARS-CoV-2 spike protein and ACE2 binding.


Screening for small molecule and antibody inhibitors is an important factor in assisting the discovery of treatments and vaccines for COVID-19 variants. ACE2, Spike, and the 3CL/Main protease are all potential therapeutic targets for the SARS-CoV-2 viral infection triggering this highly infectious disease. AMSBIO has introduced a range of Omicron assay kits for testing interactions with these targets and their respective pathways. Requiring no time-consuming wash steps, these easy-to-perform assay kits come in a variety of read-out detection methods including TR-FRET, fluorogenic, colorimetric, and chemiluminescence. These new kits are ideal for use in validation studies and suitable for rapid high-throughput screening of SARS-CoV-2 inhibitors.


Expressing B1.1.529 S protein, Omicron pseudoviruses from AMSBIO are invaluable tools for measuring inhibitory molecules when used in tandem with ACE2 recombinant cell lines or for measuring the activity neutralising antibodies. AMSBIO’s novel Omicron lentiviruses contain either luciferase or eGFP reporter genes that provide convenient readout of transduction.


Also new to the market are a range of Omicron variant recombinant proteins including Nucleocapsid protein, 3CL Protease and Spike trimer (S1+S2) developed for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.


More information online: ilmt.co/PL/aqG2 57609pr@reply-direct.com Antibodies for Bioanalysis and Drug Monitoring of Daratumumab


A range of anti-daratumumab antibodies from Bio-Rad Laboratories, Inc are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high- affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.


Daratumumab is an anticancer drug that binds to the CD38 protein overexpressed in multiple myeloma cells, leading to immune-mediated apoptosis of the tumor cell. The new range of anti-daratumumab antibodies comprises three fully human IgG1 inhibitory antibodies with varying levels of affinity. The antibodies are ideal for use as surrogate positive controls in anti-drug antibody assays, and for the development of pharmacokinetic bridging ELISAs to measure free drug.


Bio-Rad offers a portfolio of recombinant, monoclonal, nonanimal-derived anti-idiotypic antibodies and drug–target complex binders for the development of highly selective and sensitive assays. These critical reagents enable researchers to develop robust methods in a short timescale and produce translatable and reproducible results. The antibodies are generated using the Human Combinatorial Antibody Libraries (HuCAL®) and CysDisplay®, a proprietary method of phage display, along with guided selection methods to obtain highly targeted reagents.


“We are pleased to continue the expansion of our range of anti-idiotypic antibodies to support researchers developing novel treatments,” said Amanda Turner, Bio-Rad Product Manager, Life Science Group. “Our recombinant production methods result in batch-to-batch consistency, so researchers can rely on our antibodies to deliver reproducible results over the lifecycle of their bioanalytical assays,” she said.


The anti-daratumumab antibodies are approved for in vitro research purposes and for commercial applications providing in vitro testing services to support preclinical and clinical drug development. More information online: ilmt.co/PL/O1jv


57283pr@reply-direct.com


Mixer Mill for Biological Applications and Cell Disruption


Mixer mills are widely used for homogenising biological samples such as tissue, liver, muscle, plants, corn or sputum. For cell disruption via bead beating mixer mills are also the perfect solution. Retsch’s new Mixer Mill MM 500 vario is a versatile bench-top unit which provides ultimate performance with maximum flexibility for sample homogenisation. It accommodates adapters for different single- use vials of 0.2 ml/1.5 ml/2 ml/5 ml.


Depending on the tube and the type of adapter, 5-10 tubes can be inserted per adapter, resulting in the following maximum vial capacity per batch: 50 x 1.5 or 2 ml (or 60 x 0.2 ml) or 20 x 5 ml.


Typical grinding/homogenising processes of biological materials take less than 2 minutes. Cell disruption with a good reproducibility and efficiency takes 20 sec to 5 min, depending on the cell type. Cryogenic grinding in single-use vials can also be a suitable way to pulverise tough or temperature- sensitive samples in the MM 500 vario.


More information online: ilmt.co/PL/WLda 57187pr@reply-direct.com


Handheld Raman for RMID in Pharma and Other Regulated Industries


Raw material identification and verification (RMID) is a complicated process for a very important reason: it confirms the quality of the raw materials used in the manufacture of products that you put on and in your body. The complexity of RMID spans the spectrum from analytical techniques/instruments to the testing process to the governmental norms and standards that regulate all aspects of RMID including system suitability, extent of sampling, method validation, electronic records, and many others.


With MIRA P and MIRA Cal P, Metrohm Raman simplifies RMID.


Chemical analyses that historically would be performed in a laboratory by trained chemists can now be performed, very quickly and with great success, by nontechnical professionals. This relies upon a successful development of a robust method, including Raman know-how, initial data collection and development of library/operating/training sets, and model validation.


Learn all about RMID with MIRA P in these free tutorials from Metrohm: Method Development and Validation - RMID for Regulated Industries: Part I: General Considerations; Part II: Method Development; Part III: Method Robustness and Validation; Part IV: Method Implementation; Download the free tutorials from Metrohm. More information online: ilmt.co/PL/zRre


57130pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68